Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05398367 · ClinicalTrials.gov registry record · NA

Galactagogue Use in Lactating Women With Low Milk Supply

A NA study of Breast Milk Expression, sponsored by Winthrop University.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT05398367 is a NA study of Breast Milk Expression that is actively recruiting participants, run by Winthrop University. The registered enrollment target is 120 participants, above the 104-participant average among 3 other Breast Milk Expression trials with a reported enrollment target (15% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05398367, a NA study of Breast Milk Expression, is actively recruiting participants, sponsored by Winthrop University.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This study aims to determine whether a 20-day supplement with either Oat Mama Lactation Supplement, moringa, or shatavari has any impact on milk production through an increase in serum prolactin levels when compared to the placebo group. This data will be used to determine if clinical recommendations can be made for the use of the studied supplements in increasing milk supply.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Galactagogue Supplement for Treatment of Low Milk Supply

Study Locations (1)

South Carolina

  • Winthrop University - Rock Hill

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-03-05
Est. Completion 2026-06-01
Phase NA

Sponsor

Winthrop University

2 total trials

What the Registry Record Tells You About NCT05398367

The ClinicalTrials.gov registry entry for NCT05398367 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 104-participant average among 3 other Breast Milk Expression trials with a reported enrollment target (15% higher). The listed sponsor is Winthrop University, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Milk Expression appearing as the primary indexed condition, and to 1 intervention - of which Galactagogue Supplement for Treatment of Low Milk Supply is the first listed.

NCT05398367 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT05398367 about?

NCT05398367 is a clinical study titled "Galactagogue Use in Lactating Women With Low Milk Supply". This study aims to determine whether a 20-day supplement with either Oat Mama Lactation Supplement, moringa, or shatavari has any impact on milk production through an increase in serum prolactin levels when compared to the placebo group. This data will be used to determine if clinical recommendation...

What is the current status of trial NCT05398367?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-03-05. Estimated completion is 2026-06-01.

What conditions does trial NCT05398367 study?

This clinical trial studies the following conditions: Breast Milk Expression.

What interventions are being tested in trial NCT05398367?

The interventions under investigation include: Galactagogue Supplement for Treatment of Low Milk Supply (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05398367?

This trial is sponsored by Winthrop University, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05398367 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Milk Expression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.